Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 18 de 18
Filtrar
1.
Chinese Medical Sciences Journal ; (4): 29-37, 2023.
Artigo em Inglês | WPRIM | ID: wpr-981590

RESUMO

Objective We aimed to investigate whether antagonism of the cannabinoid CB1 receptor (CB1R) could affect novel object recognition (NOR) memory in chronically rapid eye movement sleep-deprived (RSD) rats.Methods The animals were examined for recognition memory following a 7-day chronic partial RSD paradigm using the multiple platform technique. The CB1R antagonist rimonabant (1 or 3 mg/kg, i.p.) was administered either at one hour prior to the sample phase for acquisition, or immediately after the sample phase for consolidation, or at one hour before the test phase for retrieval of NOR memory. For the reconsolidation task, rimonabant was administered immediately after the second sample phase.Results The RSD episode impaired acquisition, consolidation, and retrieval, but it did not affect the reconsolidation of NOR memory. Rimonabant administration did not affect acquisition, consolidation, and reconsolidation; however, it attenuated impairment of the retrieval of NOR memory induced by chronic RSD.Conclusions These findings, along with our previous report, would seem to suggest that RSD may affect different phases of recognition memory based on its duration. Importantly, it seems that the CB1R may, at least in part, be involved in the adverse effects of chronic RSD on the retrieval, but not in the acquisition, consolidation, and reconsolidation, of NOR memory.


Assuntos
Ratos , Animais , Rimonabanto/farmacologia , Memória , Sono REM , Receptores de Canabinoides , Canabinoides/farmacologia
2.
China Journal of Chinese Materia Medica ; (24): 3540-3550, 2021.
Artigo em Chinês | WPRIM | ID: wpr-888005

RESUMO

Cannabinoid receptor type 2( CB2 R),a member of the G protein-coupled receptor( GPCR) superfamily,has a variety of biological activities,such as regulating pain response,resisting inflammation and fibrosis,and mediating bone metabolism. Some CB2 R regulators exhibit a good regulatory effect on bone metabolism. Cannabinoids in Cannabis sativa can cause psychoactive effects despite various pharmacological actions they exerted by targeting CB2 R. Therefore,it is of great significance to discover CB2 R regulators in non-Cannabis plants for finding new lead compounds without psychoactive effects and elucidating the action mechanism of plant drugs. The present study clarifies the discovery,structure,and physiological functions of CB2 R,especially its regulatory effects on bone metabolism,summarized CB2 R regulators extracted from non-Cannabis plants,and systematically analyzes the regulatory effects of CB2 R regulators on bone metabolism in animals,osteoblasts,and osteoclasts,to provide a scientific basis for the discovery of new CB2 R regulators and the development of anti-osteoporotic drugs.


Assuntos
Animais , Canabinoides/farmacologia , Cannabis , Osteoblastos , Osteoclastos , Receptores de Canabinoides
3.
Acta odontol. latinoam ; 33(2): 143-152, Sept. 2020. graf
Artigo em Inglês | LILACS | ID: biblio-1130745

RESUMO

ABSTRACT The aims of the present study were, first, to identify signs of alveolar bone damage in early stages of experimental periodontitis (EP) and, second, to assess its possible prevention by treatment with cannabinoid receptor 2 agonist HU 308. Experimental periodontitis was induced by injections of lipopolysaccharide (LPS) (1mg/ml) in gums surrounding maxillary and mandibular first molar, 3 days per week, and untreated controls were kept for comparison. Then, a 3-week study was conducted including eighteen new rats (six rats per group): 1) controls; 2) experimental periodontitis rats; and 3) experimental periodontitis rats treated daily with HU 308 (500 ng/ml). After euthanasia, alveolar bone loss was assessed by morphometric and histomorphometric techniques, and the content of prostaglandin E2 (PGE2) in gingival tissue was evaluated by radioimmunoassay. The first signs of alveolar bone loss were apparent at 3 weeks of experimental periodontitis (ρ<0.05) in the mandibular first molar, but there was no detectable change at 1 week, leading us to establish 3 weeks as an early stage of experimental periodontitis. Rats subjected to 3-week experimental periodontitis showed less interradicular bone volume, less whole bone perimeter and fewer bone formation areas, and higher periodontal space height, bone resorption areas, number of osteoclasts and gingival content of prostaglandin E2 than controls, while HU 308 prevented, at least partially, the deleterious effects (ρ<0.001). We can conclude that a 3-week term of lipopolysaccharide-induced periodontitis in rats provides a valid model of the early stage of the disease, as emerging damage is observed in bone tissue. Furthermore, harmful effects at 3 weeks could be prevented by local stimulation of cannabinoid receptor 2, before greater damage is produced.


RESUMEN El objetivo del presente trabajo fue, en primer lugar, identificar signos de daño óseo alveolar en estadios tempranos de periodontitis experimental y, en segundo lugar, evaluar su posible prevención mediante el tratamiento con el agonista del receptor cannabinoide 2, HU 308. La periodontitis experimental fue inducida por inyecciones de lipopolisacárido (1mg/ml) en la encía circundante al primer molar maxilar y mandibular, 3 días por semana, en tanto que controles no tratados fueron mantenidos para la comparación. Posteriormente, un estudio de 3 semanas con dieciocho nuevas ratas (seis por grupo) fue desarrollado: 1) controles; 2) ratas con periodontitis experimental, y 3) ratas con periodontitis experimental tratadas diariamente con HU 308 (500ng/ml). Luego de la euthanasia, la pérdida ósea alveolar fue evaluada por técnicas morfométricas e histomorfométricas, y el contenido de prostaglandina E2 en el tejido gingival fue determinado por radioinmunoensayo. Los primeros signos de pérdida ósea alveolar fueron evidentes a las 3 semanas de inducción de periodontitis experimental (ρ<0.05) en el primer molar mandibular, mientras que no hubo cambios detectables luego de 1 semana de inducción, hecho que nos condujo a establecer a las 3 semanas como un estadio temprano de periodontitis experimental, Las ratas sometidas a perdiodontitis experimental de 3 semanas mostraron menor volumen óseo interradicular, menor perímetro óseo y menos áreas de formación ósea, y mayor altura del espacio periodontal, más áreas de reabsorción ósea, mayor número de osteoclastos y mayor contenido gingival de prostaglandina E2, en comparación a los controles, mientras que el tratamiento con HU 308 previno, al menos parcialmente, los efectos deletéreos (ρ<0.001). Podemos concluir que el término de 3 semanas de periodontitis inducida por lipopolisacárido es un modelo válido de estadio inicial de la enfermedad experimental, dado que se evidencia daño emergente en el tejido óseo. Asimismo, los efectos deletéreos de 3 semanas podrían ser prevenidos por la estimulación local del receptor cannabinoide 2, antes que un daño mayor sea producido.


Assuntos
Animais , Ratos , Periodontite , Osso e Ossos/efeitos dos fármacos , Canabinoides/farmacologia , Perda do Osso Alveolar/prevenção & controle , Agonistas de Receptores de Canabinoides/farmacologia , Osteoclastos , Periodontite/metabolismo , Periodontite/prevenção & controle , Perda do Osso Alveolar/metabolismo , Modelos Animais de Doenças
4.
Gac. méd. Méx ; 155(5): 471-474, Sep.-Oct. 2019. tab
Artigo em Inglês | LILACS | ID: biblio-1286545

RESUMO

Cannabis (marijuana) is one of the most consumed psychoactive substances in the world. The term marijuana is of Mexican origin. The primary cannabinoids that have been studied to date include cannabidiol and delta-9-tetrahydrocannabinol, which is responsible for most cannabis physical and psychotropic effects. Recently, the endocannabinoid system was discovered, which is made up of receptors, ligands and enzymes that are widely expressed in the brain and its periphery, where they act to maintain balance in several homeostatic processes. Exogenous cannabinoids or naturally-occurring phytocannabinoids interact with the endocannabinoid system. Marijuana must be processed in a laboratory to extract tetrahydrocannabinol and leave cannabidiol, which is the product that can be marketed. Some studies suggest cannabidiol has great potential for therapeutic use as an agent with antiepileptic, analgesic, anxiolytic, antipsychotic, anti-inflammatory and neuroprotective properties; however, the findings on cannabinoids efficacy and cannabis-based medications tolerability-safety for some conditions are inconsistent. More scientific evidence is required in order to generate recommendations on the use of medicinal cannabis.


Assuntos
Humanos , Animais , Coelhos , Canabidiol/uso terapêutico , Endocanabinoides/metabolismo , Maconha Medicinal/uso terapêutico , Suínos , Dronabinol/isolamento & purificação , Dronabinol/farmacologia , Canabidiol/isolamento & purificação , Canabinoides/farmacologia , Cannabis , Receptor CB1 de Canabinoide/metabolismo , Receptor CB2 de Canabinoide/metabolismo , Canais de Cátion TRPV/metabolismo
5.
Rev. méd. Chile ; 147(2): 206-211, Feb. 2019. tab
Artigo em Inglês | LILACS | ID: biblio-1043153

RESUMO

ABSTRACT Background: There is concern about the cognitive consequences of marijuana consumption. Aim: To assess the influence of current and past marijuana use and frequency on verbal learning and memory in a sample of adults aged 21 years old. Material and Methods: Marijuana use was assessed using a clinician administered interview in 654 participants (56% females), who reported frequency of use, age of first use and whether its use led to problems in their lives. The CogState International Shopping List was administered to assess learning and memory. Results: Seventy percent reported ever using marijuana, 46% consuming during the past year and 27% during the past 30 days. The latter scored significantly lower on delayed recall. Current and frequent use were significantly associated with lower accuracy in verbal learning and memory. Conclusions: In this cohort of adults aged 21 years old, marijuana use was prevalent and related to worse verbal memory.


Antecedentes: Existe preocupación acerca de los efectos cognitivos del consumo de marihuana. Objetivo: Estudiar el efecto de consumo de marihuana presente o pasado en la capacidad de aprendizaje verbal y memoria en una muestra de adultos de 21 años. Material y Métodos: El consumo de marihuana fue evaluado mediante una entrevista médica en 654 adultos de 21 años (56% mujeres), quienes informaron acerca de la frecuencia de consumo, edad de comienzo y si el consumo les ha causado problemas en sus vidas. Se les administró el Cogstate International Shopping List para evaluar aprendizaje y memoria. Resultados: El 70% informó haber consumido marihuana alguna vez, 46% la usó durante el último año y el 27% en los últimos 30 días. Estos últimos tuvieron un menor puntaje en memoria tardía. El consumo actual y frecuente se asoció a una menor precisión en la capacidad de aprendizaje verbal y memoria. Conclusiones: En esta cohorte de adultos de 21 años, el consumo de marihuana fue prevalente y relacionado a una menor memoria verbal.


Assuntos
Humanos , Masculino , Feminino , Adulto Jovem , Rememoração Mental/efeitos dos fármacos , Aprendizagem Verbal/efeitos dos fármacos , Canabinoides/farmacologia , Uso da Maconha/epidemiologia , Memória/efeitos dos fármacos , Fatores de Tempo , Chile/epidemiologia , Abuso de Maconha/etiologia , Abuso de Maconha/epidemiologia , Estudos Transversais , Transtornos Cognitivos/complicações , Uso da Maconha/efeitos adversos , Testes Neuropsicológicos
6.
Medisan ; 21(3)mar. 2017.
Artigo em Espanhol | LILACS | ID: biblio-841678

RESUMO

Intensa resulta la controversia entre los que promueven el uso de los cannabinoides con fines terapéuticos y quienes consideran que es temprana aún la introducción de estos en la clínica, por sus efectos deletéreos para la salud humana en las diferentes etapas y condicionales del desarrollo biológico. Paralelamente se debate, entre las autoridades encargadas de velar por la salud de sus conciudadanos, la polémica de legalizar o no el consumo de la Cannabis sativa en cualquiera de sus formas y derivados naturales. Ambas polémicas han fundamentado el estudio de todas las formas de presentación y consumo de esta planta, así como de sus derivados sintéticos dados sus efectos sobre la salud de enfermos y sanos. En esta breve reseña se exponen aspectos relevantes de su farmacología, debido al interés y enorme caudal de información generado por un sinnúmero de investigadores dedicados al estudio de dicha planta y sus derivados


The controversy among those that promote the use of cannabinoids with therapeutic aims is intense and who consider that it is still early for their introduction in the clinic, due to their lethal effects for the human health in the different stages and conditionals of the biological development. In parallel it is debated, among the authorities in charge of looking after the health of their fellow citizens, the polemic of legalizing or not the consumption of the Cannabis sativa in any of their forms and natural derived. Both polemics have based the study of all the forms of presentation and consumption of this herb, as well as of its synthetic derived due to their effects on the health of sick and healthy people. In this brief review outstanding aspects of their pharmacology are exposed, due to the interest and enormous flow of information generated by a large number of investigators dedicated to the study of this herb and its derived elements


Assuntos
Humanos , Canabinoides/uso terapêutico , Canabinoides/farmacologia , Uso de Medicamentos/legislação & jurisprudência , Maconha Medicinal/farmacologia , Cannabis , Endocanabinoides/antagonistas & inibidores
7.
Invest. clín ; 56(2): 188-200, jun. 2015. ilus, graf
Artigo em Espanhol | LILACS | ID: biblio-841078

RESUMO

Una de las causas más importantes de morbilidad y mortalidad es la disfunción neurológica; su alta incidencia ha estimulado una intensa búsqueda de mecanismos para proteger al sistema nervioso central de situaciones que producen hipoxia e isquemia. El mayor reto es interrumpir los eventos bioquímicos que involucra y que llevan a la muerte neuronal. Esto puede conseguirse a través de la neuroprotección que tiene por objeto frenar las cascadas inmunológica y metabólica que aparecen después de un daño neurológico agudo. Cuando esto sucede, se producen eventos fisiopatológicos que incluyen la producción de citocinas, el estrés oxidante y la excitotoxicidad. Respecto a todos esos mecanismos, se han reportado efectos protectores de los endocanabinoides, los cuales parecen ser neuroprotectores en modelos animales de isquemia cerebral, excitotoxicidad, trauma cerebral y en enfermedades neurodegenerativas. Algunos análogos de canabinoides se encuentran actualmente en evaluación (fases clínicas I-III) para el tratamiento de enfermedades agudas que involucran a la muerte neuronal (isquemia y trauma cerebrales). El estudio del sistema canabinoide podría generar agentes neuroprotectores efectivos de amplio espectro de acción para el tratamiento de afecciones neurológicas en un futuro cercano.


One of the most important causes of morbidity and mortality is neurologic dysfunction; its high incidence has led to an intense research of the mechanisms that protect the central nervous system from hypoxia and ischemia. The mayor challenge is to block the biochemical events leading to neuronal death. This may be achieved by neuroprotective mechanisms that avoid the metabolic and immunologic cascades that follow a neurological damage. When it occurs, several pathophysiological events develop including cytokine release, oxidative stress and excitotoxicity. Neuroprotective effects of cannabinoids to all those mechanisms have been reported in animal models of brain ischemia, excitotoxicity, brain trauma and neurodegenerative disorders. Some endocannabinoid analogs are being tested in clinical studies (I-III phase) for acute disorders involving neuronal death (brain trauma and ischemia). The study of the cannabinoid system may allow the discovery of effective neuroprotective drugs for the treatment of neurological disorders.


Assuntos
Animais , Humanos , Canabinoides/farmacologia , Isquemia Encefálica/tratamento farmacológico , Doenças Neurodegenerativas/tratamento farmacológico , Isquemia Encefálica/fisiopatologia , Citocinas/metabolismo , Estresse Oxidativo/fisiologia , Fármacos Neuroprotetores/farmacologia , Neurônios/patologia
8.
Rev. chil. pediatr ; 85(2): 229-237, abr. 2014. ilus
Artigo em Espanhol | LILACS | ID: lil-711585

RESUMO

Ya son varios los países que han aceptado la marihuana como una droga "blanda", diferente a otras más peligrosas. Incluso se le ha atribuido diversas propiedades terapéuticas. Otros sin embargo piensan que su uso debería prohibirse, dadas las interferencias mentales y las alteraciones del comportamiento que produce, ya sea por su consumo esporádico, como también por los daños permanentes a que lleva su consumo crónico. Con el objeto de aclarar estas divergentes apreciaciones, se revisa la literatura científica existente. De ello se deduce el grave riesgo de su consumo crónico, especialmente para el adolescente por el significativo incremento de cuadros psicóticos y esquizofrénicos, los cuales pueden llegar a ser permanentes, mientras que su consumo durante el embarazo daña el desarrollo cerebral del feto en forma similar a lo que hace el alcohol en el síndrome fetal alcohólico. Investigaciones científicas también señalan que al fumar sus hojas, se va produciendo un daño bronquial, aún más grave que con el tabaco, incluyendo el cáncer pulmonar. En conclusión, el concepto de que la marihuana es una droga "blanda", libre de riesgos para la salud, constituye un grave error, dado la concluyente investigación científica disponible que señala lo contrario.


There are already several countries that have accepted marijuana as a soft drug, separating it from more dangerous ones. Yarious therapeutic properties have even been attributed to its use. Others, however, think that its use should be prohibited due to the mental interference and behavioral changes produced either by its occasional use as well as the permanent mental damage linked to chronic marijuana use. In order to clarify this divergence of opinions, the scientific literature is reviewed. It is concluded that there is a serious risk, especially for teenagers, associated to chronic marijuana use due to the presence of more frequent psychotic and schizophrenic episodes, which can be permanent, while consumption during pregnancy results in brain damage to the fetus, similar to fetal alcohol syndrome. Scientific research also indicated that smoking marijuana produces an even more severe bronchial damage than tobacco, with risk of lung cancer. In conclusion, the notion that marijuana is a risk-free soft drug is a serious mistake, based on the available conclusive scientific research that shows the opposite.


Assuntos
Humanos , Canabinoides/farmacologia , Fumar Maconha/legislação & jurisprudência , Dronabinol/farmacologia
9.
West Indian med. j ; 61(3): 264-270, June 2012. ilus
Artigo em Inglês | LILACS | ID: lil-672898

RESUMO

Cannabis sativa is one of the oldest herbal remedies known to man. Over the past four thousand years, it has been used for the treatment of numerous diseases but due to its psychoactive properties, its current medicinal usage is highly restricted. In this review, we seek to highlight advances made over the last forty years in the understanding of the mechanisms responsible for the effects of cannabis on the human body and how these can potentially be utilized in clinical practice. During this time, the primary active ingredients in cannabis have been isolated, specific cannabinoid receptors have been discovered and at least five endogenous cannabinoid neurotransmitters (endocannabinoids) have been identified. Together, these form the framework of a complex endocannabinoid signalling system that has widespread distribution in the body and plays a role in regulating numerous physiological processes within the body. Cannabinoid ligands are therefore thought to display considerable therapeutic potential and the drive to develop compounds that can be targeted to specific neuronal systems at low enough doses so as to eliminate cognitive side effects remains the 'holy grail' of endocannabinoid research.


La cannabis sativa es una especie herbácea usada en uno de los remedios herbarios más viejos conocidos al ser humano. Durante los últimos cuatro mil anos, se ha usado para el tratamiento de numerosas enfermedades, pero debido a sus propiedades psicoactivas, su uso medicinal actual se halla muy restringido. En este estudio, se busca resaltar los adelantos hechos durante los últimos cuarenta anos en cuanto a entender los mecanismos responsables de los efectos del cannabis sobre el cuerpo humano, y cómo éstos pueden utilizarse potencialmente en la práctica clínica. Durante este tiempo, se han aislado los ingredientes activos primarios en el cannabis, se han descubierto receptores canna-binoides específicos, y se han identificado por lo menos cinco neurotransmisores endógenos (endo-cannabinoides). Juntos, éstos forman la estructura de un complejo sistema de senalización endocannabinoide, el cual tiene una amplia distribución en el cuerpo y desempena un papel en la regulación de numerosos procesos fisiológicos dentro del organismo. Por tanto, se piensa que los ligandos cannabinoides despliegan un considerable potencial terapêutico. Así, el dinamismo para desarrollar compuestos que puedan ser dirigidos a sistemas neuronales en dosis suficientemente bajas como para eliminar los efectos cognitivos secundarios, sigue siendo el "santo grial" de la investigación de los endocannabinoides.


Assuntos
Animais , Humanos , Canabinoides/uso terapêutico , Cannabis , Endocanabinoides/fisiologia , Canabinoides/farmacologia , Endocanabinoides/farmacologia , Endocanabinoides/uso terapêutico
11.
Artigo em Português | LILACS | ID: lil-482130

RESUMO

OBJETIVO: A maconha é a droga ilícita mais consumida no mundo, porém ainda existem poucos estudos examinando eventuais prejuízos cognitivos relacionados ao seu uso. As manifestações clínicas associadas a esses déficits incluem síndrome amotivacional, prejuízo na flexibilidade cognitiva, desatenção, dificuldade de raciocínio abstrato e formação de conceitos, aspectos intimamente ligados às funções executivas, as quais potencialmente exercem um papel central na dependência de substâncias. O objetivo do estudo foi fazer uma revisão a respeito das implicações do uso da maconha no funcionamento executivo. MÉTODO: Esta revisão foi conduzida utilizando-se bases de dados eletrônicas (MedLine, Pubmed, SciELO and Lilacs). DISCUSSÃO: Em estudos de efeito agudo, doses maiores de tetrahidrocanabinol encontram-se associadas a maior prejuízo no desempenho de usuários leves em tarefas de controle inibitório e planejamento; porém, este efeito dose-resposta não ocorre em usuários crônicos. Embora haja controvérsias no que se refere a efeitos residuais da maconha, déficits persistentes parecem estar presentes após 28 dias de abstinência, ao menos em um subgrupo de usuários crônicos. CONCLUSÕES: Os estudos encontrados não tiveram como objetivo principal a avaliação das funções executivas. A seleção de testes padronizados, desenhos de estudos mais apropriados e o uso concomitante com técnicas de neuroimagem estrutural e funcional podem auxiliar na melhor compreensão das conseqüências deletérias do uso crônico da maconha no funcionamento executivo.


OBJECTIVE: Cannabis is the most used illicit drug worldwide, however only a few studies have examined cognitive deficits related to its use. Clinical manifestations associated with those deficits include amotivational syndrome, impairment in cognitive flexibility, inattention, deficits in abstract reasoning and concept formation, aspects intimately related to the executive functions, which potentially exert a central role in substance dependence. The objective was to make a review about consequences of cannabis use in executive functioning. METHOD: This review was carried out on reports drawn from MedLine, SciELO, and Lilacs. DISCUSSION: In studies investigating acute use effects, higher doses of tetrahydrocannabinol are associated to impairments in performance of nonsevere users in planning and control impulse tasks. However, chronic cannabis users do not show those impairments. Although demonstration of residual effects of cannabis in the executive functioning is controversial, persistent deficits seem to be present at least in a subgroup of chronic users after 28 days of abstinence. CONCLUSIONS: The neuropsychological studies found did not have as a main aim the evaluation of executive functioning. A criterial selection of standardized neuropsychological tests, more appropriate study designs as well as concomitant investigations with structural and functional neuroimaging techniques may improve the understanding of eventual neurotoxicity associated with cannabis use.


Assuntos
Humanos , Canabinoides/farmacologia , Transtornos Cognitivos/induzido quimicamente , Cognição/efeitos dos fármacos , Abuso de Maconha/psicologia , Fumar Maconha/efeitos adversos , Atenção/efeitos dos fármacos , Transtornos Cognitivos/fisiopatologia , Formação de Conceito/efeitos dos fármacos , Tomada de Decisões , Lobo Frontal/efeitos dos fármacos , Comportamento Impulsivo/induzido quimicamente , Comportamento Impulsivo/fisiopatologia , Comportamento Impulsivo/psicologia , Fumar Maconha/fisiopatologia , Fumar Maconha/psicologia , Testes Neuropsicológicos , Dronabinol/toxicidade
13.
Rev. farm. bioquim. Univ. Säo Paulo ; 29(2): 55-61, jul.-dez. 1993. ilus, tab
Artigo em Português | LILACS | ID: lil-135288

RESUMO

A Cannabis (maconha) tem sido utilizada como droga de abuso por varias decadas, ocupando o primeiro lugar entre as drogas ilicitas usadas atualmente em todo o mundo. Sendo seu uso proibido entre nos, e de importancia forense a identificacao do usuario atraves da analise toxicologica do componente principal responsavel pela psicoatividade da droga (THC) bem como de seu principal produto de biotransformacao (THC-COOH) em amostras biologicas. Com a finalidade de fornecer informacoes a respeito dos aspectos botanicos, quimicos, farmacologicos, toxicologicos bem como da legislacao vigente de aspecto legal preparou-se esta monografia


Assuntos
Humanos , Botânica , Cannabis , Química , Canabinoides/farmacologia , Dronabinol/toxicidade , Drogas Ilícitas
14.
Artigo em Inglês | IMSEAR | ID: sea-21200

RESUMO

The effect of cannabis extract, on the hepatic aminopyrine-N-demethylase activity was studied in rats. Daily administration of cannabis extract for 15 consecutive days increased the aminopyrine-N-demethylase activity which was significant on day 15 post-treatment at 2 and 10 mg/kg doses. At 20 mg/kg, a significant increase was observed from day 7 which continued up to day 15. These findings suggest that cannabis extract can induce hepatic aminopyrine-N-demethylase activity.


Assuntos
Aminopirina N-Desmetilase/biossíntese , Animais , Canabinoides/farmacologia , Indução Enzimática/efeitos dos fármacos , Masculino , Mitocôndrias Hepáticas/enzimologia , Ratos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA